High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors

Manpreet K. Chadha, Jeffrey Lombardo, Terry Mashtare, Gregory E. Wilding, Alan Litwin, Cheryl Raczyk, John F. Gibbs, Boris Kuvshinoff, Milind M. Javle, Renuka V. Iyer

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Background: Long-acting sandostatin (S-LAR; octreotide acetate) is well tolerated and effective for symptom control and possibly disease control in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We undertook a retrospective analysis to study the efficacy and tolerability of higher doses (more than 20-30 mglmonth) of S-LAR in GEP-NETs. Patients and Methods: With IRB approval, charts of all patients with GEP-NET who received S-LAR between June 2002 to September 2007 at Roswell Park Cancer Institute were reviewed and their data analyzed. Results: Fifty- four patients with GEP-NET received S-LAR; thirty required dose escalation. Patients received a median of 5 doses of S-LAR at conventional dose followed by up-titration of the dose for symptom control (20) and radiological progression (17). Median high dose of S-LAR was 40 mg (range: 40-90 mg) with a median of 8.5 high doses received. No treatment related toxicities were seen. The estimated 1-year survival for patients on conventional dose alone was 0.77 (95% CI of 050 to 0.91) and those on high-dose was 0.88 (95% CI of 0.68 to 0.96) (p=0.4777) while median time to any other intervention was 2.9 months versus 17.7 months (p=0.12). Conclusion: Dose escalation of S-LAR is well tolerated and may provide longer disease control.

Original languageEnglish (US)
Pages (from-to)4127-4130
Number of pages4
JournalAnticancer Research
Issue number10
StatePublished - Oct 2009

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this